The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic
Get full access to this article
View all access options for this article.
References
1.
KantarjianH., ThomasD., O'BrienS.. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer.2004; 101: 2788–2801.
2.
KhouriI.F., RomagueraJ., KantarjianH.. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol.1998; 16: 3803–3809.
3.
ThomasD.A., CortesJ., O'BrienS.. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol.1999; 17: 2461–2470.
4.
RomagueraJ.E., KhouraI.F., KantarjianH.M.. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma.2000; 39: 77–85.
5.
DonthireddyV., KambojG., JanakiramanN.Retrospective review of patients with aggressive lymphomas treated with hyper-CVAD regimen—our institutional experience [abstract]. J Clin Oncol.2004; 22: 6736.
6.
ThomasD.A., O'BrienS., CortesJ.. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood.2004; 104: 1624–1630.
7.
Garcia-ManeroG., KantarjianH.M.The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin of North Am.2000; 14: 1381–1396.
8.
KantarjianH., O'BrienS., SmithT.L.Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol.2000; 18: 547–561.
9.
WeiserM.A., O'BrienS., ThomasD., PierceS.A., LamT.P., KantarjianH.M.Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer.2002; 94: 285–291.
10.
KollerC.A., KantarjianH.M., ThomasD.. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia.1997; 11: 2039–2044.
11.
ThomasD.A., FadelS., O'BrienS.. Chemo-immunotherapy with hyper-CVAD plus Rituximab for adult Burkitt's and Burkitt's type lymphoma (BL) or acute lymphoblastic leukemia (B-ALL). Blood.2005; 106: abstract: 149.
12.
RomagueraJ.E., FayadL.E., WangM.. High (95%) Response rates in relapsed/refractory mantle cell lymphoma after R-HCVAD alternating with R-methotrexate/cytarabine (R-M-A). Blood.2005; 106: abstract: 2446.
13.
RomagueraJ.E., FayadL., RodriguezM.A.. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol.2005; 23: 7013–7023.
14.
ThomasD.A., FaderlS., CortesJ.. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood.2004; 103: 4396–4407.
15.
KohL.P., LimL.C.Cerebellar toxicity following hyperCVAD regimen for acute lymphoblastic leukaemia. Br J Haematol.1999; 104: 644–645.
16.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36: 740–745.
17.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–109.
18.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Available at: http://www.nccn.org/. Accessed April 4, 2006.
19.
Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. 2005. Available at: http://www.mascc.org/. Accessed April 3, 2006.
20.
StillwellT.J., BensonR.C.Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61: 451–457.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol.2003; 30(Suppl 13): 10–17.
25.
OzerH., ArmitageJ.O., BennettC.L.. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000;18: 3558–3585.
26.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–1799.
27.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–402.
28.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
